Summary Mediastinal masses include a wide variety of tumours and remain an interesting diagnostic challenge for radiologists. We performed positron emission tomography (PET) studies of primary mediastinal tumours in order to predict the malignancy of these tumours preoperatively. Twenty-two patients with primary mediastinal tumours were studied with PET using 2-deoxy-2-[18F]fluoro-D-glucose (FDG). The Rendina et al., 1988) . The CT demonstration of fat, calcium or water attenuation in a tumour often suggests a specific diagnosis. However, the ability of CT to differentiate soft tissue mediastinal masses is limited, owing to a considerable overlap in the CT characteristics between malignant and benign tumours (Rendina et al., 1988; Rebner et al., 1987) .
Mediastinal masses include a wide variety of tumours, and remain an interesting diagnostic challenge for radiologists. Computerised tomography (CT) has proved to be an excellent diagnostic tool for investigating the mediastinum (Cohen et al., 1991; Davis et al., 1987; Graeber et al., 1986) . CT can delineate the location and extent of mediastinal tumours, as well as the involvement of adjacent tissue. Whereas obliteration of the peritumoral fat planes corresponds with invasion and is a sign of malignancy, fibrous adhesion of the tumour without invasion may be confused with infiltration of the tumour. When the fat planes are partially preserved, only about half of the tumours are invasive (Chen et al., 1988; Rendina et al., 1988) . The CT demonstration of fat, calcium or water attenuation in a tumour often suggests a specific diagnosis. However, the ability of CT to differentiate soft tissue mediastinal masses is limited, owing to a considerable overlap in the CT characteristics between malignant and benign tumours (Rendina et al., 1988; Rebner et al., 1987) .
Magnetic resonance imaging (MRI) is also useful in evaluating mediastinal tumours (Aronberg et al., 1985; Brown et al., 1991) . The advantages of MRI are direct multiplane imaging of tumour invasion. MRI has a better contrast resolution and is more reliable than CT in detecting cystic tumours, fat in a tumour and vascular diseases. However, an overlap in Ti and T2 parameters of MRI has been demonstrated between benign and malignant tumours (Link et al., 1993) .
Positron emission tomography (PET) has proved excellent in detecting malignant tumours of the central nervous system (CNS) and non-CNS tumours (Strauss and Conti, 1991) . Both 2-deoxy-2-fluoro-[18F]-D-glucose (FDG) and L- methionine (Met) have been used with PET for the diagnosis of head and neck (Minn et al., 1988; LeskinenKallio et al., 1992) , breast (Leskinen-Kallio et al., 1991; Wahl et al., 1991) , and lung (Kubota et al., 1990 , Patz et al., 1993 cancers. FDG has also been used in detecting liver tumours PET imaging and analysis Twenty-two patients were studied using FDG. FDG was prepared using an automated synthesis system, and quality assurance tests were performed as described previously (Kubota et al., 1990) . After fasting for 5 h the blood glucose level was measured before the injection of FDG. PET scans were performed using a PT931/04 scanner (Siemen-CTI, Knoxville, TN, USA) employing seven 7.15-mm wide slices, simultaneous acquisition, with 50 mm axial field of view (resolution: 7.1 mm of full-width half-maximum (FWHM).
No tumour was smaller than 2.5 cmx3.0 cm in diameter, and we considered that the calibration of the count recovery might not be essential because it is said that an object of the size three times larger than FWHM shows more than 80% of count recovery (Mazziota et al., 1981) . After a transmission scan using germanium-68/gallium-68 ring source for the attenuation correction, a bolus dose of FDG was injected intravenously. The mean dose of FDG was 4.8 + 0.8 mCi (177.6 + 29.6 MBq). Dynamic images were obtained first, followed by a 10 min static image that was acquired 45-55 min after injection of FDG. The PET images were reconstructed using a measured attenuation, dead time and decay correction factors. There was no significant patient movement or mis-positioning between transmission scan and emission scan. This was checked with the markers attached to the patient and the laser pointers of the scanner during the examination. Evaluation of data was performed before tissue biopsy or surgery and histological diagnosis. Static images on film were examined and compared with CT scans by four observers (KK, HF, TF, MI). In order to have the anatomical orientation of the PET image, CT images were used. Then, the tumour uptake was assessed by an observer (KK), using the region of interest (ROI) technique. The tumour ROI was set on the static image. In large tumours ROI was placed at the periphery of tumour including the highest radioactivity point, so that it included minimum necrotic tissue. The actual size of the tumour ROI varied from 2 to 6 cm2 depending on the tumour size. To avoid contamination of the non-tumour area, the tumour ROls were checked carefully by superimposing both on transmission images and on the early post injection images, which showed vascular structures. The mean radioactivity per pixel within the tumour ROI was quantitatively analysed by calculating the differential uptake ratio (DUR; synonym standardised uptake value, SUV), as reported previously (Kubota et al., 1985) .
DUR Radioactivity concentration in ROI (Bq mm-3)
Injected dose (Bq)/weight of patient (g)
Mean DURs in tumour groups were compared with mean DURs in the benign lesions using Student's t test.
CT and pathological diagnosis All patients had CT imaging within 2 weeks before the PET study. The image level of the PET study was determined by CT and chest radiological examination. Because only a few patients had MRI in this study, the results of MRI were not reported in the present study. CT images were evaluated before PET study. Diagnostic criterion of invasiveness with CT is based on the obliteration of the peritumoral fat planes or signs of direct invasion to adjacent structures. Histological diagnosis was determined in all patients after the PET study by surgical pathology (14 patients) or biopsy (eight patients), and the histological diagnosis was compared with results of the PET study. Thymic tumours were classified as cytological benign (thymoma) or malignant (thymic cancer) depending on the conventional cytological criteria. Thymoma was classified as invasive or non-invasive. It is based on the microscopic demonstration of tumour cell invasion to the outside of the capsule of the tumours resected by surgery, biopsy or macroscopic demonstration of gross invasion of tumour tissue to adjacent structure by mediastinoscopy. Invasive thymoma is considered as clinically malignant, and non-invasive thymoma as clinically benign.
Results
The clinical characteristics of patients and results of FDG studies are shown in Table I . A high FDG uptake (DUR >4) was clearly observed in nine of ten patients with clinically malignant tumours, and also in one patient with sarcoidosis. A moderate level of FDG (DUR> 1.5) uptake was observed in non-invasive thymomas, a myeloma and schwannoma, whereas a low FDG uptake (1.5 > DUR) was detected in a teratoma and various benign cysts. The cut-off line of malignant tumour seems to be about 3.5 by DUR. The mean FDG uptake was significantly higher in clinically malignant tumours compared with that of benign tumour using DUR (Table II) . The blood glucose levels in malignant tumours were not significantly different from those in benign tumours. The mean body mass index of benign tumours was slightly higher than that of malignant tumours. Example of typical PET images of invasive thymoma (Figure 1 ) and noninvasive thymoma (Figure 2 ) are presented.
Variable results were obtained with CT. In general, a specific diagnosis using CT was difficult when the tumour showed a soft tissue density. We, therefore, examined the CT in the diagnosis of tumour invasion (Table I) . False-negative results were noted in two cases of invasive thymomas and a case of Hodgkin's disease, and false-positive in a non-invasive thymoma with fibrous adhesions demonstrated during surgery. Another false positive CT was noted in a bronchogenic cyst. CT correctly diagnosed the tumour invasion in 17 patients (sensitivity 70%, specificity 83%, accuracy 77%). FDG-PET showed a false positive of sarcoidosis, and a false negative of a myeloma and correctly predicted the nature of the tumour in 20 patients (sensitivity 90%, specificity 92%, accuracy 91%). Thus, in this limited series of patients, PET seems to be superior to CT in predicting the nature of mediastinal tumours.
The distribution of DUR in malignant and benign tumours with FDG is shown (Figure 3) . The use of FDG enabled differentiation of most malignant tumours from benign tumours based on DUR analysis. However, there was an overlap between malignant and benign tumours. Table III summarises the FDG uptake by thymic tumours. Invasive thymomas showed significantly higher FDG uptake than non-invasive thymomas (P < 0.005) and other benign tumours (P<0.001). Thymic cancer showed the same high FDG uptake as invasive thymoma. 
Discussion
The major finding of the present study is that the distribution of FDG uptake in malignant mediastinal tumours, revealed by PET, was significantly higher than that in benign tumours. These results are in agreement with those reported recently on the excellent diagnostic performance of PET in differentiating the malignancy of lung nodules using FDG-PET. These studies demonstrated that the sensitivity of FDG-PET in detecting lung cancers of more than 1 cm in diameter as malignant tumours was 95-98% with a specificity of 83-94% (Kubota et al., 1990; Patz et al., 1993; Dewan et al., 1993) . The present results are also consistent with FDG-PET studies of other tumours, including breast (Adler et al., 1993) and pancreatic tumours (Bares et al., 1994) . These results suggest that the high uptake of FDG seems to be a general feature of a variety of cancers. Increased FDG uptake may reflect the high activity of hexokinase and glucose transport (Haberkorn et al., 1994) .
Calculation of the glucose metabolic rate using FDG based on Sokoloffs model has been applied to oncology PET, mostly to brain tumour studies (Di Chiro, 1987 FDG uptake of lung and head and neck tumours decreased significantly in the presence of hyperglycaemia (Lindholm et al., 1993; Langen et al., 1993) . Our study did not include such obese patients as they have reported (BW 80-107 kg) and, furthermore, the blood glucose level was the same in patients with malignant and benign tumours. Therefore, technical errors in our PET measurements are unlikely.
A false-positive high FDG uptake was observed in sarcoidosis in the present study. Similar studies have recently described increased FDG uptake by enlarged lymph nodes (Lewis and Salama, 1994) and lung tissue (Brudin et al., 1994) in sarcoidosis. Since sarcoid nodules consist of PET for mediastinal tumours K Kubota et al 885 epidermoid cells that have, together with the macrophages, a common precursor cell, the monocyte, we believe that the high FDG uptake by the sarcoid tissue is a similar phenomenon to that by macrophages. This is supported by experimental demonstration of increased FDG uptake by macrophages (Kubota et al., 1992) .
The level of FDG uptake of tumours is related to the grade of malignancy in brain and soft tissue tumours (Di Chiro, 1987; Adler et al., 1991) . Furthermore, it has also been used as a prognostic indicator of malignancy in gliomas (Patronas et al., 1985) . The FDG uptake by the tumour also correlates with the cell density in grade 2 and 3 gliomas (Herholz et al., 1993) . Results of experimental studies indicate that the uptake of FDG is related to the number of viable cancer cells in vitro (Higashi et al., 1993) , and the amount of viable tissue in vivo (Kubota et al., 1993) . FDG uptake varies also with the histological differentiation of human abdominal tumours transplanted in nude mice (Yoshioka et al., 1994) . In this regard, recent studies from our laboratory indicate that FDG uptake by cancer cells is higher in GO/GI and G2 phases of the cell cycle compared with the S-and M-phases (Kubota et al., 1994) , and that tumour growth rates correlated with the FDG uptake of tumours (Kubota et al., 1995) . These results suggest that uptake of FDG by mediastinal tumours may represent a biological marker of the clinical behaviour of these tumours.
Thymomas are classified cytologically into benign or malignant. However, a proportion of the cytologically benign thymomas is locally invasive and has clinical features of malignancy. Thus, cytological classification may not be always prognostically useful (Lewis et al., 1987) . Our PET study demonstrated a high FDG uptake by thymic cancers and invasive thymomas. These results add support to the clinical practice that both thymic cancers and invasive thymomas should be treated as malignant tumours, while only non-invasive thymomas should be considered benign tumours (Lewis et al., 1987) . The classification of thymomas by PET in the present study agreed with the clinical rather than the cytological classification. However, owing to the small number of patients, a further confirmation of this observation is necessary.
Single-photon emission computerised tomography (SPECT) using 67Ga or 20'T1 has been used widely for tumour imaging. Usefulness of 67Ga-SPECT for malignant lymphoma in mediastinum has been well established (Front et al., 1991) . However, the uptake of 67Ga is non-specific for malignant tumour (Tsan and Scheffel, 1986; Chandramouly et al., 1989) . The value of 67Ga for the differential diagnosis of mediastinal tumour seems not to be high. 201TI-SPECT has been used recently for the diagnosis of lung and other tumours (Abdel-Dayem et al., 1994) . Detection of thymoma in patients of myasthenia gravis has been reported with 201Tl-SPECT. However, they cannot differentiate malignant tumour from benign thymoma (Tonami et al., 1993) .
In conclusion, PET, using FDG, seems to be useful in the evaluation of malignancy in primary mediastinal tumours. Both thymic cancer and invasive thymoma showed high FDG uptake, while non-invasive thymomas and other benign tumours showed low uptake. A high FDG uptake seems to reflect the invasiveness or malignant nature of thymic tumours.
